B6;SJL-Slc6a3^{tm1.1(cre)Bkmn}/J

Stock number: 006302
Research areas: Cell Biology Research, Neurobiology Research, Research Tools

Description

These dopamine transporter IRES-cre (DAT^IREScre) mutant mice exhibit co-localization of Cre recombinase and endogenous Slc6a3 (solute carrier family 6 (neurotransmitter transporter, dopamine), member 3) gene expression and may be useful in neurobiological studies to facilitate the analysis of gene function in dopaminergic neurons, such as drug addiction or Parkinson's disease.
This strain is discontinued. Please refer to B6.SJL-Slc6a3^{tm1.1(cre)Bkmn}/J Stock No. 006660.

Detailed description

Mice homozygous for this dopamine transporter IRES-cre (DAT^IREScre or DAT-cre) mutant allele are viable and fertile. Cre recombinase activity is observed as early as embryonic day 15, and co-localizes with endogenous gene expression in adult dopaminergic cell groups (substantia nigra (SN) and ventral tegmental area (VTA), as well as in the retrorubral field). Lower Cre recombinase activity is detected in adult olfactory bulb glomeruli, mimicking the known lower Slc6a3 (or DAT) expression in this tissue. Although the pattern and intensity of DAT immunostaining in the SN, VTA and striatum do not differ between wildtype and mutant mice, striatum DAT protein levels are moderately reduced (17%) in heterozygotes and significantly reduced (47%) in homozygotes. This decrease in DAT protein levels in homozygous mutant striatum is associated with significantly increased neuropeptide PDyn (but not D1, D2, or PPE) mRNA levels compared to wildtype. Increases in these mRNA levels are not observed in heterozygotes. When these mice are bred with mice containing a loxP-flanked ("floxed") sequence of interest, cre-mediated recombination will result in deletion of the flanked genome in dopaminergic neurons in the cre-positive, homozygous floxed offspring. These mutant mice may facilitate gene function analysis in dopaminergic neurons in neurological studies of, for example, drug addiction or Parkinson's disease.

Allele

Symbol: Slc6a3^{tm1.1(cre)Bkmn}
Name: targeted mutation 1.1, Cristina M Backman
MGI accession ID: MGI:3689434
Generation method: Targeted
Attributes: Recombinase-expressing
Synonyms: (DAT)::Cre; Dat^IRESCre; Dat^IREScre; DATCre; DAT-IRES-Cre
Marker symbol: Slc6a3
Marker name: solute carrier family 6 (neurotransmitter transporter, dopamine), member 3
Marker synonyms: DAT; Dat1; PKDYS; PKDYS1
Chromosome: 13
Strain of origin: Not Specified
Expressed genes: cre,cre recombinase,bacteriophage P1
Site of expression: Cre recombinase activity is observed as early as embryonic day 15, and co-localizes with endogenous gene expression in adult dopaminergic cell groups (substantia nigra (SN) and ventral tegmental area (VTA), as well as in the retrorubral field). Lesser Cre recombinase activity occurs in adult olfactory bulb glomeruli, mimicking the known lower Slc6a3 (or DAT) expression in this tissue.
Molecular note: An FRT-flanked neo was removed from the locus, leaving cre recombinase cDNA in the 3' UTR to allow bicistronic mRNA expression.
General note: The targeting vector was electroporated into both R1 and C57BL/6 ES cells.